| Biomarker ID | 49 |
| PMID | 15289328 |
| Year | 2004 |
| Biomarker | phosphorylated Akt (pAkt) + phosphorylated ERK (extracellular signal-regulated kinase) (pERK) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | pAKT: Upregulated in PSA failures; pERK: Downregulated in PSA failures |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-CD40/CD40L signaling, PI3K/PLC/TRK pathway,PI3K/PLC/TRK pathwayPI3K/AKT act,Inactivation of GSK3 by Akt causes accumulation of beta-catenin in alveolar macrophagesivation |
| Experiment | PSA failure versus PSA non failure |
| Type of Biomarker | Prognostic |
| Cohort | 53 patients with PCa were selected for the study out of which 37 had PSA failure and 16 did not have PSA failure |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.84 |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | total staining was scored as the product of the staining intensity (on a scale of 0–3) x the percentage of cells stained, resulting in a scale of 0–300 |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | AKT1, ERK |